Clinical trials: Hydroxychloroquine
Type1 Diabetes Mellitus
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.
- Trial name
- TN-22 (NCT03428945)
- Testing
- Hydroxychloroquine
- Where
- 51 sites in United States, Australia and 4 more
- Volunteers
- 273 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Systemic Lupus Erythematosus
Study of Anti-Malarials in Incomplete Lupus Erythematosus
This project is a multicenter, randomized, placebo-controlled, double-blind clinical trial that is designed to test whether treating patients who are at risk for development of lupus with hydroxychloroquine can slow accumulation…
- Trial name
- SMILE (NCT03030118)
- Testing
- Hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 187 people
- Sponsor
- Milton S. Hershey Medical Center
Virus Diseases, Infection Viral
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.
- Conditions
- Virus Diseases, Infection Viral, Corona Virus Infection
- Trial name
- ProPAC-COVID (NCT04322396)
- Testing
- Azithromycin, Hydroxychloroquine
- Where
- 8 sites in Denmark
- Volunteers
- 117 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Interstitial Lung Disease, Diffuse Parenchymal Lung Disease
Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)
This is an exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.
- Conditions
- Interstitial Lung Disease, Diffuse Parenchymal Lung Disease, Children´s Interstitial Lung Disease
- Trial name
- HCQ-chILD-EU (NCT02615938)
- Testing
- Hydroxychloroquine sulfate
- Where
- 9 sites in Germany
- Volunteers
- 35 people
- Sponsor
- Matthias Griese
SARS-CoV-2
Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection
This is a pragmatic, randomized, open-label, incomplete factorial with nested randomization clinical trial evaluating the efficacy and safety of two potential treatments for hospitalized patients with confirmed SARS-CoV-2…
- Trial name
- NCT04335552
- Testing
- Standard of care, Hydroxychloroquine, Azithromycin
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Duke University